Dissociation of Thrombin's substrate interactions using site-directed mutagenesis

Trends in Cardiovascular Medicine

Volumn 10, Issue 2, 2000, Pages 89-92

  Leung, Lawrence L K ^a   Hall, Scott W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; PROCOAGULANT; PROTEIN C; THROMBIN; THROMBOMODULIN;

ALLOSTERISM; BINDING SITE; BLOOD CLOTTING; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME BINDING; ENZYME SUBSTRATE COMPLEX; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SITE DIRECTED MUTAGENESIS;

EID: 0034532008     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(00)00047-5     Document Type: Review

References (25)

1. The safety and efficacy of a TAFIa inhibitor in a rabbit arterial thrombolysis and bleeding model
2. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
3. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
4. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
5. Coagulation-dependent inhibition of fibrinolysis; role of carboxypeptidase U and the premature lysis of clots from hemophilic plasma
6. + binding site of thrombin
7. An update on clinical and basic aspects of the protein C anticoagulant pathway
8. Endothelial protein C receptor
9. Conversion of thrombin into an anticoagulant by protein engineering
10. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains
11. Antithrombotic effects of selective activation of endogenous protein C
12. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
13. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
14. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor
15. Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity
16. Structure-function studies of the epidermal growth factor domains of human thrombomodulin
17. Plasma carboxypeptidases as regulators of the plasminogen system
18. The structure of a complex of recombinant hirudin and human alpha-thrombin
19. Prothrombin deficiency results in embryonic and neonatal lethality in mice
20. Functional mapping of the surface residues of human thrombin
21. Functional domains of membrane-bound human thrombomodulin
22. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo
23. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice
24. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alters its specificity
25. Inhibitor of plasma carboxypeptidase B as a novel fibrinolytic enhancer for thrombolytic therapy